All In Biotech

Drug Trial Radar · NCT06333483

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

A Single-Arm, Open-Label, Phase I Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients With Severe, Refractory Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Actual

Start

Feb 2, 2024

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Autolus LimitedIndustry
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, to establish the tolerability, safety, preliminary efficacy, and pharmacokinetics of obe-cel in patients with severe, refractory SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Obecabtagene autoleucel (obe-cel)Biological

    Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a single dose of obe-cel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicitiesTime frame: Up to 28 days from obe-cel infusion
  2. Adverse eventsTime frame: Up to Month 12

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital Universitari Vall Hebrón

    Barcelona, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

  • Manchester Royal Infirmary, Manchester University NHS Foundation Trust,

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.